Viome is betting on biotech.
What’s happening: The preventative health company acquired Sōlaria Biō, adding bone health therapeutics to its test-to-treat care stack.
Well-equipped. Building on microbiome testing, precision nutrition, and personalized supplements, Sōlaria adds another layer to Viome’s whole-body approach.
Using AI to decode a biobank of 5.7K+ plant-derived microbes, Sōlaria developed pre/probiotic supplement Bōndia, shown to improve bone loss by 85%. Influencing the gut-bone axis, the company targets anyone 35+, but especially women entering menopause.
Instant access. Part of a broader shift toward data-driven care delivery, Viome acquired Circulate Health, adding toxin-reducing therapeutic plasma exchange to its expanding ecosystem, while a Microsoft partnership connects and contextualizes molecular data at scale.
Sōlaria’s platform will give consumers ready-to-use solutions for gut barrier, bone density, and joint health — while its next clinical-stage candidate is being reviewed for rheumatoid arthritis and healthy aging.
Looking ahead: As microbiome platforms move beyond measurement, Viome is turning insights into validated interventions, making health data the entry point, not the final touchpoint.
